A 38-year-old man with established rheumatoid arthritis has been on methotrexate 20 mg/week for 4 months. Despite good compliance and adequate dosing, his DAS28 score remains 5.8 (high disease activity), and he has active synovitis in 8 joints. His baseline investigations show negative RF but positive anti-CCP antibodies. What is the preferred next step in pharmacological management?

Explanation

## Management of MTX-Inadequate Response in RA **Key Point:** When a patient fails to achieve remission or low disease activity on optimized conventional DMARD monotherapy (MTX at target dose for ≥8–12 weeks), the next step is to add a biologic agent, preferably a TNF-α inhibitor. ### Treatment Algorithm for Inadequate MTX Response ```mermaid flowchart TD A[RA on MTX 20 mg/week]:::outcome --> B{Response after 8-12 weeks?}:::decision B -->|Remission/LDA| C[Continue MTX monotherapy]:::action B -->|Inadequate response| D[Add biologic DMARD]:::action D --> E{First-line biologic?}:::decision E -->|Yes| F[TNF-α inhibitor ± MTX]:::action E -->|TNF failure| G[Switch to non-TNF biologic]:::action F --> H[Reassess at 12 weeks]:::decision H -->|Remission| I[Maintain combination]:::outcome H -->|Still inadequate| J[Optimize or switch biologic]:::action ``` ### Why Add a Biologic (TNF Inhibitor)? 1. **Evidence-based**: ACR/EULAR guidelines mandate biologic addition if inadequate response to optimized conventional DMARD 2. **Superior efficacy**: TNF inhibitors + MTX achieve remission in ~40% of MTX-inadequate responders vs. ~15% with MTX intensification alone 3. **Prevents progression**: Halts radiographic joint damage and functional decline 4. **Synergistic effect**: TNF inhibitors work via different mechanism (cytokine blockade) than MTX (antimetabolite) ### TNF-α Inhibitors Available in India | Agent | Route | Dosing | Monitoring | |-------|-------|--------|------------| | Etanercept | SC | 25 mg twice weekly | TB screening, FBC, LFTs | | Infliximab | IV | 3 mg/kg at 0, 2, 6 weeks, then 8-weekly | TB screening, infusion reactions | | Adalimumab | SC | 40 mg every 2 weeks | TB screening, LFTs | **Clinical Pearl:** Always screen for latent TB (IGRA or TST) and active infection before initiating TNF inhibitors; TB reactivation is a serious risk. **High-Yield:** The "treat-to-target" strategy mandates reassessment at 12 weeks post-biologic initiation; if still inadequate response, escalate to non-TNF biologic (abatacept, rituximab) rather than persisting with same agent. **Mnemonic:** **BIOLOGIC ENTRY CRITERIA** = **BEC** - **B**aseline MTX ≥15 mg/week for ≥8 weeks - **E**arly inadequate response (DAS28 > 3.2 or CDAI > 10) - **C**ontinue MTX + add biologic (do not stop MTX) [cite:Harrison 21e Ch 297; ACR 2021 RA Guidelines]